A Novel Polymer-Encapsulated Multi-Imaging Modality Fiducial Marker with Positive Signal Contrast for Image-Guided Radiation Therapy

Li Wang, Jeremiah Sanders, John F. Ward, Stephen R. Lee, Falk Poenisch, David Swanson, Narayan Sahoo, Xiaorong Zhu, Jingfei Ma, Rajat J. Kudchadker, Seungtaek Choi, Quynh‐Nhu Nguyen, Lauren L. Mayo, Shalin Shah, Steven J. FrankCancers 2024 · DOI

TL;DR

This paper introduces NOVA, a novel polymer-encapsulated fiducial marker designed for image-guided radiation therapy (IGRT) in prostate cancer. NOVA offers superior visibility across multiple imaging modalities (kV X-ray, ultrasound, CT, MRI) with significantly reduced artifacts and radiation dose perturbations compared to existing gold and carbon markers, paving the way for more precise and safer cancer treatments.

What Problem Does This Paper Address?

External-beam radiotherapy (EBRT) is a cornerstone treatment for prostate cancer (PCa). However, achieving optimal outcomes hinges on precisely targeting the tumor while sparing surrounding healthy tissues. This precision is challenged by the limitations of current fiducial markers (FMs), which are implanted to guide treatment. Existing FMs often suffer from poor visibility on MRI, create significant artifacts on CT and MRI, and can perturb radiation dose distributions, potentially leading to under- or over-treatment. These issues hinder accurate image registration, especially when fusing CT and MRI data, which is increasingly crucial for advanced treatment planning. The need for an FM that is reliably visible across all relevant imaging modalities, minimizes artifacts, and has minimal impact on radiation dose is critical for advancing IGRT in PCa.

Methods

The researchers evaluated a novel fiducial marker, NOVA, alongside two established markers: Gold Anchor (gold) and BiomarC (carbon). Their methodology involved several key steps:

  • Imaging Modality Evaluation: Phantoms with implanted FMs were imaged using kilovoltage (kV) X-ray, transrectal ultrasound (TRUS), computed tomography (CT), and magnetic resonance imaging (MRI) to assess visibility.
  • CT Artifact Quantification: A metric called the relative streak artifacts level (rSAL) was used to quantify artifacts on CT images.
  • Proton Radiation Dose Perturbation (PDP) Assessment: Radiochromic film was used to measure the dose perturbation caused by each FM when placed perpendicular and parallel to the proton beam axis at various depths. Statistical analysis (F-tests) was employed to determine the significance of marker type, orientation, and distance on PDP.
  • Clinical Case Study: The NOVA marker's performance was evaluated in a patient undergoing EBRT for prostate cancer, focusing on its utility in daily positioning, MRI/CT co-image registration, and treatment plan generation.

Datasets

Not discussed in the paper. The study primarily used tissue-equivalent phantoms and one patient for evaluation.

Key Insights and Ideas

  • True Multimodality Visibility: Unlike existing markers, NOVA is positively visible across kV X-ray, TRUS, CT, and MRI. This is a significant advantage for comprehensive treatment planning and daily alignment.
  • Reduced Artifacts: NOVA exhibits substantially smaller CT artifacts (lower rSAL and rSD values) compared to Gold Anchor markers. This is crucial for accurate delineation of tumors and organs at risk.
  • Minimal Dose Perturbation: NOVA causes significantly less proton dose perturbation, particularly at clinically relevant depths, compared to both Gold Anchor and BiomarC markers. This is vital for ensuring dose accuracy in proton therapy.
  • MRI Positive Contrast: The ability of NOVA to provide a positive signal on MRI, without the susceptibility artifacts seen with gold markers, is a game-changer for MRI/CT fusion and planning.
  • Clinical Feasibility: The successful application of NOVA in a patient demonstrated its practical utility for daily positioning, MRI/CT fusion, and generating more precise treatment plans.

Key Results

  • Visibility: NOVA FMs were positively visualized on all four tested imaging modalities (kV, TRUS, CT, MRI).
  • CT Artifacts: NOVA markers showed smaller artifacts on CT compared to Gold Anchor markers, with rSAL values of 0.750 ± 0.335 for 2-mm slices.
  • Proton Dose Perturbation: At a depth of 5 mm, NOVA FMs caused significantly less proton dose perturbation (4.5%) compared to Gold Anchor (12.9%) and Carbon FMs (6.0%). Even at greater depths, NOVA's perturbation remained lower.
  • Clinical Application: In a patient, NOVA FMs facilitated MRI/CT image fusion, accurate contouring of organs, and the generation of a treatment plan that provided more precise soft tissue anatomy visualization than CT-alone planning.

Limitations and Future Work

  • Long-Term Stability: The paper acknowledges that the long-term stability and intraprostatic migration/rotation of NOVA markers are crucial and have not yet been studied. While the marker has a fixation device, future studies with more patients are needed to address this.
  • Limited Comparative FMs: The study compared NOVA to only two other commercially available FMs (one gold, one carbon). A broader systematic comparison with other FMs is suggested for future work.
  • In Vitro vs. In Vivo: The phantom studies, while informative, have inherent limitations due to the artificial environment. The authors note that patient anatomy is more heterogeneous.

Future work should focus on long-term stability studies, larger patient cohorts to confirm clinical benefits, and potentially a more extensive comparison with a wider range of existing fiducial markers.

Summary updated

Abstract

NOVA-FMs were positively visible and produced less PDP than G-FMs or C-FMs. NOVA-FMs facilitated MRI/CT fusion and identification of regions of interest.
BibTeX
@inproceedings{wang2024novel,
  author = {Li Wang and Jeremiah Sanders and John F. Ward and Stephen R. Lee and Falk Poenisch and David Swanson and Narayan Sahoo and Xiaorong Zhu and Jingfei Ma and Rajat J. Kudchadker and Seungtaek Choi and Quynh‐Nhu Nguyen and Lauren L. Mayo and Shalin Shah and Steven J. Frank},
  title = {{A Novel Polymer-Encapsulated Multi-Imaging Modality Fiducial Marker with Positive Signal Contrast for Image-Guided Radiation Therapy}},
  booktitle = {Cancers},
  year = {2024},
  doi = {10.3390/cancers16030625},
}
Figure